EAU London Unveiled

Chinese Experts Shine on the World’s Top Urology Stage

The 41st European Association of Urology (EAU) Congress was grandly held in London, UK, from March 13–16, 2026. As one of the most influential urological academic events in Europe and globally, the conference brought together over 15,000 top experts and scholars from more than 110 countries to focus on cutting-edge developments and breakthroughs in urology. It served as a core platform for academic exchange and cooperation in the global urological field.

At this prestigious international academic gathering, Director Cui Di of Shanghai First People's Hospital was invited to give a keynote speech, representing Chinese urology and sharing the latest clinical research progress on Low-Intensity Pulsed Ultrasound (LIPUS) technology, led by Professor Han Bangmin and Director Cui Di’s team. This achievement, presented at an international top-level conference, not only showcases the global academic influence of the urology team at Shanghai First People's Hospital but also marks the successful international recognition of China's homegrown medical technology, offering new hope to patients suffering from erectile dysfunction (ED) and post-prostatectomy incontinence worldwide.

Clinical Pain Points: The "Unspoken Struggles" of Post-Prostatectomy and ED, Urgently Needing Minimally Invasive Solutions

Robot-assisted radical prostatectomy (RARP) is currently one of the main treatments for prostate cancer. However, post-surgical incontinence, a common complication, has become a key challenge affecting patient recovery quality. Uncontrolled leakage of urine not only causes inconvenience but also leads to social withdrawal and psychological burdens, significantly diminishing the patient’s post-surgery quality of life. At the same time, the prevalence of erectile dysfunction (ED) continues to rise globally, also seriously impacting men's physical and mental health and family happiness.

According to the latest 2024 AUA guidelines, post-prostatectomy incontinence (PPI) has become a clinical focal point for rehabilitation. Achieving effective functional recovery without surgery, while ensuring treatment safety, to help patients restore physiological functions and regain their dignity, has become a pressing need in the global urology field.

Technological Breakthrough: LIPUS Opens New Pathways for Minimally Invasive Rehabilitation, with Unique Advantages in China’s Approach

To address the above clinical pain points, the innovative application of Low-Intensity Pulsed Ultrasound (LIPUS) technology has brought together the expertise and collaborative efforts of top urologists both in China and abroad. Led by authoritative experts such as Academician Guo Yinglu, Professor Lü Futai, and Professor Xia Shujie, a multi-center clinical research platform was established by seven top-tier hospitals in China. This has laid a solid evidence-based medical foundation for the standardized promotion of LIPUS technology, from technical exploration to clinical applications in ED.

Professor Han Bangmin and Director Cui Di of Shanghai First People's Hospital have been deeply involved in male health and post-prostatectomy rehabilitation. With a keen understanding of LIPUS's unique non-invasive advantages in treating post-prostatectomy incontinence, they led their team to conduct systematic research, providing patients with safer and more effective rehabilitation options. After years of clinical validation, LIPUS technology has shown remarkable core advantages:

High Safety: Non-invasive treatment avoids surgical trauma and adverse drug reactions. Clinical observations confirm its good safety in the treatment of post-prostatectomy incontinence.

Precise Action: Mechanical micro-stimulation promotes tissue repair, improving both the function of the urinary sphincter and the blood supply to erectile tissues, aligning with the precision rehabilitation concept.

Convenience: Treatment duration is moderate, with a regular frequency, fitting post-surgical rehabilitation cycles and long-term management needs, which significantly enhances patient compliance.

The LIPUS medical device used in this EAU presentation was independently developed by the domestic company Beijing WBL Medical Co., Ltd.

 Research Highlights: LIPUS Treatment for Post-Prostatectomy Incontinence, Excellent Efficacy and Safety

At the conference, Director Cui Di shared the clinical research results of Low-Intensity Pulsed Ultrasound for treating post-prostatectomy incontinence. The study adopted a rigorous double-blind controlled design, with all patients undergoing standard pelvic floor muscle training and basic interventions. The scientific rigor of the study received high recognition from international peers, with the preliminary results standing out:

1.The LIPUS treatment group showed significant improvement in incontinence symptoms, with faster recovery in urinary leakage compared to the control group.

2.Recovery of urinary control function accelerated, with patients significantly shortening their reliance on incontinence pads.

3.No notable adverse events were reported during the treatment, further confirming the technology’s excellent safety.

With solid research data, clear academic logic, and cutting-edge treatment concepts, this study has sparked widespread attention and in-depth discussion among global experts, providing a new approach to the diagnosis and treatment of related diseases, with a fresh perspective from China.

Future Prospects: China’s LIPUS Continues to Lead, Bringing Chinese Wisdom to Benefit Global Patients

The core goal of treating prostate cancer and ED is not only "curing the disease" but also improving the patient's quality of life and restoring their dignity. The Chinese urology team has always adhered to this medical philosophy. Under the leadership of industry-leading experts, they continue to delve into LIPUS technology research, offering more patient-centered treatment options through innovative exploration.

This achievement presented at the EAU conference is a high recognition of China’s academic level and clinical contributions in the international academic community, and a testament to the ongoing rise of China’s urology team’s global influence. In the future, the urology team at Shanghai First People's Hospital will continue to collaborate with multiple centers to deepen research, refine data, and optimize treatment plans, driving the standardized and widespread development of LIPUS technology.

We look forward to the combined efforts of many Chinese urology experts, so that this non-invasive treatment technology, originating from China, can benefit more ED and post-prostatectomy incontinence patients worldwide, helping them return to healthy lives and social happiness, and letting Chinese medical wisdom shine even brighter in the global male health field.